The role and mechanism of m6A methylation in diabetic nephropathy

被引:0
|
作者
Yan, Linjing [1 ]
Guo, Liang [1 ]
机构
[1] Shanghai Univ Sport, Shanghai Frontiers Sci Res Base Exercise & Metab H, Shanghai 200438, Peoples R China
基金
中国国家自然科学基金;
关键词
m6A methylation; Diabetic nephropathy; Writers; Erasers; Readers; MESSENGER-RNA; NUCLEAR-RNA; MESENCHYMAL TRANSITION; M(6)A METHYLATION; KIDNEY-DISEASE; CELL; RECOGNITION; BINDING; N6-METHYLADENOSINE; PROTEINS;
D O I
10.1016/j.lfs.2024.123355
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Diabetic nephropathy (DN) is one of the most common microvascular complications of diabetes mellitus, characterized by progressive deterioration of renal structure and function, which may eventually lead to endstage kidney disease (ESKD). The N6-methyladenosine (m6A) methylation, an important modality of RNA modification, involves three classes of key regulators, writers (e.g., METTL3), erasers (e.g., FTO, ALKBH5) and readers (e.g., YTHDF2), which play important roles in DN. Writers are responsible for introducing m6A modifications on RNAs, erasers remove m6A modifications and readers recognize and bind m6A-modified RNAs to regulate RNAs functions, such as mRNA stability, translation and localization. In DN, abnormal m6A modification may promote kidney injury and proteinuria by regulating key pathways involved in multiple processes, including lipid metabolism and inflammatory response, in kidney cells such as podocytes. Therefore, an in-depth study of the role and mechanism of m6A methylation that are regulated by "writers", "erasers" and "readers" in DN is expected to provide new targets and strategies for the prevention and treatment of DN.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Role of N6-Methyladenosine (m6A) Methylation Regulators in Hepatocellular Carcinoma
    Qu, Nanfang
    Bo, Xiaotong
    Li, Bin
    Ma, Lei
    Wang, Feng
    Zheng, Qinghua
    Xiao, Xuhua
    Huang, Fengmei
    Shi, Yuanyuan
    Zhang, Xuemei
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [42] The Role of N6-Methyladenosine (m6A) Methylation Modifications in Hematological Malignancies
    Zhao, Yan
    Peng, Hongling
    CANCERS, 2022, 14 (02)
  • [43] Molecular characterization of m6A RNA methylation regulators with features of immune dysregulation in IgA nephropathy
    Wang, Yihao
    Sun, Nan
    He, Rui
    Wang, Zida
    Jin, Jingsi
    Gao, Ting
    Qu, Junwen
    CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
  • [44] The role and mechanism of m6A methylation modification of LncRNA-ATB in regulating the invasion and metastasis of colorectal cancer
    Lang, Yu
    Lin, Jia-Lin
    Kang, Jia-Peng
    Yang, Lu
    Zhou, Dan
    Fang, Can-Bin
    Ye, Feng
    Tang, Wei-wei
    CANCER RESEARCH, 2024, 84 (06)
  • [45] Crosstalk Between Histone and m6A Modifications and Emerging Roles of m6A RNA Methylation
    Xu, Zibin
    Xie, Tingfei
    Sui, Xiaolu
    Xu, Yunpeng
    Ji, Lecai
    Zhang, Yanzi
    Zhang, Aisha
    Chen, Jihong
    FRONTIERS IN GENETICS, 2022, 13
  • [46] RNA m6A methylation regulators in sepsis
    Zhu, Lin
    Zhang, Hairong
    Zhang, Xiaoyu
    Xia, Lei
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2024, 479 (09) : 2165 - 2180
  • [47] RNA m6A methylation across the transcriptome
    Sendinc, Erdem
    Shi, Yang
    MOLECULAR CELL, 2023, 83 (03) : 428 - 441
  • [48] m6A RNA Methylation in Cardiovascular Diseases
    Wu, Siyi
    Zhang, Shuchen
    Wu, Xiaoguang
    Zhou, Xiang
    MOLECULAR THERAPY, 2020, 28 (10) : 2111 - 2119
  • [49] The Role of m6A Modification and m6A Regulators in Esophageal Cancer
    Li, Yuekao
    Niu, Chaoxu
    Wang, Na
    Huang, Xi
    Cao, Shiru
    Cui, Saijin
    Chen, Tianyu
    Huo, Xiangran
    Zhou, Rongmiao
    CANCERS, 2022, 14 (20)
  • [50] The role of m6A RNA methylation in autoimmune diseases: Novel therapeutic opportunities
    Shan, Yunan
    Chen, Wei
    Li, Yanbin
    GENES & DISEASES, 2024, 11 (01) : 252 - 267